Abstract
Growth/differentiation factor 15 (GDF15), also known as MIC-1, is a distant member of the transforming growth factor-β (TGF-β) superfamily and has been implicated in various biological functions, including cancer cachexia, renal and heart failure, atherosclerosis and metabolism1. A connection between GDF15 and body-weight regulation was initially suggested on the basis of an observation that increasing GDF15 levels in serum correlated with weight loss in individuals with advanced prostate cancer2. In animal models, overexpression of GDF15 leads to a lean phenotype, hypophagia and other improvements in metabolic parameters3, suggesting that recombinant GDF15 protein could potentially be used in the treatment of obesity and type 2 diabetes. However, the signaling and mechanism of action of GDF15 are poorly understood owing to the absence of a clearly identified cognate receptor. Here we report that GDNF-family receptor α-like (GFRAL), an orphan member of the GFR-α family, is a high-affinity receptor for GDF15. GFRAL binds to GDF15 in vitro and is required for the metabolic actions of GDF15 with respect to body weight and food intake in vivo in mice. Gfral−/− mice were refractory to the effects of recombinant human GDF15 on body-weight, food-intake and glucose parameters. Blocking the interaction between GDF15 and GFRAL with a monoclonal antibody prevented the metabolic effects of GDF15 in rats. Gfral mRNA is highly expressed in the area postrema of mouse, rat and monkey, in accordance with previous reports implicating this region of the brain in the metabolic actions of GDF15 (refs. 4,5,6). Together, our data demonstrate that GFRAL is a receptor for GDF15 that mediates the metabolic effects of GDF15.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adela, R. & Banerjee, S.K. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J. Diabetes Res. 2015, 490842 (2015).
Brown, D.A. et al. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum. 56, 753–764 (2007).
Chrysovergis, K. et al. NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism. Int. J. Obes. (Lond) 38, 1555–1564 (2014).
Borner, T. et al. Anorexia–cachexia syndrome in hepatoma tumour–bearing rats requires the area postrema but not vagal afferents and is paralleled by increased MIC-1/GDF15. J. Cachexia Sarcopenia Muscle 8, 417–427 (2016).
Johnen, H. et al. Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1. Nat. Med. 13, 1333–1340 (2007).
Tsai, V.W. et al. The anorectic actions of the TGFβ cytokine MIC-1/GDF15 require an intact brainstem area postrema and nucleus of the solitary tract. PLoS One 9, e100370 (2014).
Bootcov, M.R. et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc. Natl. Acad. Sci. USA 94, 11514–11519 (1997).
Unsicker, K., Spittau, B. & Krieglstein, K. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev. 24, 373–384 (2013).
Mueller, T.D. & Nickel, J. Promiscuity and specificity in BMP receptor activation. FEBS Lett. 586, 1846–1859 (2012).
Airaksinen, M.S. & Saarma, M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3, 383–394 (2002).
Airaksinen, M.S., Holm, L. & Hätinen, T. Evolution of the GDNF family ligands and receptors. Brain Behav. Evol. 68, 181–190 (2006).
Cik, M. et al. Binding of GDNF and neurturin to human GDNF family receptor alpha 1 and 2. Influence of cRET and cooperative interactions. J. Biol. Chem. 275, 27505–27512 (2000).
Parkash, V. et al. The structure of the glial cell line–derived neurotrophic factor–coreceptor complex: insights into RET signaling and heparin binding. J. Biol. Chem. 283, 35164–35172 (2008).
Li, Z. et al. Identification, expression and functional characterization of the GRAL gene. J. Neurochem. 95, 361–376 (2005).
Lutz, T.A., Mollet, A., Rushing, P.A., Riediger, T. & Scharrer, E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int. J. Obes. Relat. Metab. Disord. 25, 1005–1011 (2001).
Ahima, R.S. & Antwi, D.A. Brain regulation of appetite and satiety. Endocrinol. Metab. Clin. North Am. 37, 811–823 (2008).
Day, H.E., McKnight, A.T., Poat, J.A. & Hughes, J. Evidence that cholecystokinin induces immediate early gene expression in the brainstem, hypothalamus and amygdala of the rat by a CCKA receptor mechanism. Neuropharmacology 33, 719–727 (1994).
Riediger, T., Zuend, D., Becskei, C. & Lutz, T.A. The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut–brain axis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R114–R122 (2004).
Dill, M.J., Shaw, J., Cramer, J. & Sindelar, D.K. 5-HT1A receptor antagonists reduce food intake and body weight by reducing total meals with no conditioned taste aversion. Pharmacol. Biochem. Behav. 112, 1–8 (2013).
Wang, F. et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn. 14, 22–29 (2012).
Acknowledgements
We thank J. Shou, X. Wu and D. Accili for helpful suggestions on the manuscript.
Author information
Authors and Affiliations
Contributions
P.J.E., M.D.G., T.C., R.S., R.E.G., B.B.Z., B.S. and X.W. designed and supervised the research. F.W., Y.D., Q.L., R.T.P., T.C., M.J.H., K.K.B., D.K.S., L.A.F., A.M., J.A.-F., G.C.B., J.X.T., X.L., X.M., P.J.M. and J.H.S. performed research. P.J.E., M.D.G., T.C., R.S. and X.W. analyzed data. P.J.E. and X.W. wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
All authors declare competing financial interests as employees of Eli Lilly and Company.
Supplementary information
Supplementary Figures and Table
Supplementary Figures 1–6 and Supplementary Table 1. (PDF 620 kb)
Rights and permissions
About this article
Cite this article
Emmerson, P., Wang, F., Du, Y. et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med 23, 1215–1219 (2017). https://doi.org/10.1038/nm.4393
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4393
This article is cited by
-
Artesunate treats obesity in male mice and non-human primates through GDF15/GFRAL signalling axis
Nature Communications (2024)
-
Genetic determinants of plasma protein levels in the Estonian population
Scientific Reports (2024)
-
Obesity and the kidney: mechanistic links and therapeutic advances
Nature Reviews Endocrinology (2024)
-
Is There a Role for Growth and Differentiation Factor-15 in B-Cell Lymphoproliferative Neoplasms?
Indian Journal of Hematology and Blood Transfusion (2024)
-
GDF15 induces chemoresistance to oxaliplatin by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis in colorectal cancer
Cellular Oncology (2024)